Apr 11, 2018 Treatment Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta agonist, in Primary Biliary Cholangitis Patients: 12- and 26-Week Analyses of an Ongoing, International, Randomized, Dose Ranging Phase 2 Study
Oct 24, 2017 Treatment Efficacy and Safety of Low Dose Seladelpar a Selective PPAR-δ Agonist, in Patients with Primary Biliary Cholangitis: 12-week Interim Analysis of an International, Randomized, Dose Ranging, Phase 2 Study
Oct 16, 2017 Concordance of Pruritus Scales in Primary Biliary Cholangitis (PBC) Patients: Pruritus Visual Analogue Scale (VAS) and 5-D Itch in Clinical Trial Settings
Apr 24, 2017 Proof Of Efficacy For Seladelpar, A Selective Ppar- Agonist, In Patients With Primary Biliary Cholangitis Non-responsive To Ursodeoxycholic Acid: Results Of An International Phase 2 Randomized Controlled Clinical Study
Apr 4, 2017 Activity of Seladelpar (MBX-8025), a Potent and Selective PPAR-δ Agonist, on Biochemical Markers of Cholestasis
Apr 4, 2017 Biochemical Profile in 68 Primary Biliary Cholangitis (PBC) Subjects Having an Inadequate Response to Ursodeoxycholic Acid
Feb 1, 2017 A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) who are inadequate responders to ursodeoxycholic acid (UDCA)
Nov 11, 2016 Clinical Study Start-up Time Lines for Rare Orphan Diseases: Can We Do Better? The Example of Primary Biliary Cholangitis
Sep 1, 2016 A Pilot study of MBX-8025 in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
